Donald L. Novajosky
Donald L. Novajosky joined Slipakoff, PC in April 2015. Don is an experienced general counsel and corporate lawyer, with over 15+ years of experience advising corporate boards and executives of privately-held and publicly-traded companies in the software, IT, pharmaceutical, and biotechnology industries on a wide variety of domestic and international legal matters, with an emphasis on corporate, securities/SEC, M&A and corporate governance matters.
Don previously served as VP, General Counsel & Secretary of Webtrends, a global provider of web analytics and optimization solutions. While at Webtrends, Don lead the company’s Legal Department and was responsible for all legal matters affecting the company, including general corporate, commercial contracts, compliance, data security & privacy, intellectual property, and litigation and dispute resolution.
Don also served, for several years, as SVP, General Counsel & Secretary of Aptean (formerly, CDC Software, NASDAQ: CDCS), a global leader in enterprise application software and related services that provides vertical industry-specific CRM, ERP, SCM, and e-commerce solutions in SaaS, cloud, and on-premise deployments; and at Aptean’s former parent company, CDC Corporation (NASDAQ: CHINA), a Hong Kong-based holding company of software, IT, online gaming, and internet portal/media businesses.
While at Aptean and CDC, Don served as compliance officer, lead the companies’ world-wide legal team, and was responsible for corporate, securities/SEC, M&A, commercial, compliance, corporate governance, risk management, and litigation matters. In addition, while at CDC, Don oversaw the acquisition of, or investment in, over 30+ businesses located in the US, EMEA, Australia, Hong Kong, China, India and South America, to supplement and expand the companies’ business and product offerings,
Don has served as an attorney with several well-known law firms including Wilmer Cutler Pickering Hale and Dorr (WilmerHale), Buchanan Ingersoll Rooney, Reed Smith, and Hutchison Law Group, where his practice focused on general corporate matters, securities and SEC reporting, M&A, corporate governance, technology licensing, regulatory compliance, and corporate transactions, for technology-focused clients.
Don also served as Director, Legal for Cytogen Corporation (NASDAQ: CYTO), a publicly-traded biopharmaceutical company with an established product line in prostate cancer therapeutics and other areas of oncology.